A Phase 3 interventional study of Placebo plus standard therapy and Belimumab 10 mg/kg plus standard therapy in Lupus Nephritis, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 118 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.
Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 4th largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2012, is one of 16 in phase 3, and was the 21st registered.
343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.
Browse Lupus Nephritis studies →39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
iCell Gene Therapeutics · Sites in United States
Ages 16–70
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 47 · Phase 3 17 · Phase 4 7
First in 1994; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 448 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.
Median enrollment 50 across the 100 interventional studies, 265 across the 14 observational. Of the 53 that completed or were terminated, 31 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 114 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
GlaxoSmithKline has 3 studies filed under Lupus Nephritis — fewer than ten, so there is no comparison to draw.
11 of the studies in Lupus Nephritis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
| NCT06518668Hospital for Special Surgery, New YorkA Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus | 2026-12 |
| NCT06375993Adicet TherapeuticsA Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease | 2026-12 |
| NCT06217107Morehouse School of MedicineWellness & Workforce Solution for Lupus/Lupus Nephritis | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 114 studies in Lupus Nephritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients with active lupus nephritis.
Study participants receive standard therapy (induction and maintenance) for lupus nephritis in addition to receiving either placebo (no active medicine) or belimumab. Induction therapy starts before the first dose of study drug (belimumab or placebo). Maintenance therapy begins after completion of induction therapy and continues for the remainder of the study. Participants receive study drug throughout the entire study, during both induction and maintenance periods. The controlled period of the study is 104 weeks. The random assignment in this study is "1 to 1" which means you have an equal chance of receiving treatment with belimumab or placebo. Participants who successfully complete the 104-week study may enter into a 6-month open-label extension. All participants in the open-label extension receive belimumab.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
Biological: Placebo plus standard therapy · Drug: Standard therapy
Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
Biological: Belimumab 10 mg/kg plus standard therapy · Drug: Standard therapy
Placebo plus standard therapy
Drug page: Belimumab
Belimumab 10 mg/kg plus standard therapy
Also known as: BENLYSTA™
The standard therapies allowed in this study are: - High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy OR - High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy
Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104
PERR is defined as urinary protein creatinine ratio \<=0.7, estimated glomerular filtration rate (eGRF) was not more than 20 percent (%) below the pre-flare value or \>=60 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2) and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates treatment group, induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline urine protein-creatinine ratio (uPCR), and Baseline eGFR. Modified Intent-to-treat (mITT) Population consisted of all randomized participants who received at least one dose of study treatment and were not excluded due to Good Clinical Practice (GCP) non-compliance. Percentage of participants with PERR at Week 104 has been presented.
Time frame: Week 104
Open-label Period: Number of Participants Reporting Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.
Time frame: From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)
Open-label Period: Number of Participants Reporting Adverse Events of Special Interest (AESI)
An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths.
Time frame: From first open-label dose (Day 1) up to open-label Week 32 (8 weeks after last dose)
Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104
CRR is defined as urinary protein creatinine ratio \<0.5, eGRF was not more than 10% below the pre-flare value or \>=90 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline uPCR and Baseline eGFR. Percentage of participants with CRR at Week 104 has been presented.
Time frame: Week 104
Double-blind Period: Percentage of Participants With PERR at Week 52
PERR is defined as urinary protein creatinine ratio \<=0.7, eGRF was not more than 20% below the pre-flare value or \>=60 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), uPCR, and Baseline eGFR. Percentage of participants with PERR at Week 52 has been presented.
Time frame: Week 52
Double-blind Period: Number of Participants With Time to Death or Renal Related Event
Events are defined as the first event experienced among the following: death, progression to end stage renal disease, doubling of serum creatinine from Baseline, renal worsening or renal-related treatment failure. Participants who discontinued randomized treatment, withdrew from the study, were lost to follow-up, or had a non renal-related treatment failure were censored. Participants who completed the 104-week treatment period were censored at the Week 104 visit. Time to event is defined as event date minus treatment start date plus one. Analysis was performed using Cox proportional hazards model for the comparison between Belimumab and Placebo adjusting for induction regimen, race, Baseline uPCR and Baseline eGFR. Number of participants with time to death or renal related event up to Week 104 has been presented.
Time frame: Up to Week 104
Double-blind Period: Percentage of Participants With Ordinal Renal Response (ORR) at Week 104
ORR is defined with respect to reproducible responses that included CRR, partial RR (PRR) and non responder. CRR is reported when uPCR was \<0.5, eGFR was not more than 10% below pre-flare GFR or within normal range and not a treatment failure. PRR is \>=50% decrease from Baseline in uPCR and one of the following: value \<1 if Baseline \<=3, or value \<3 if the Baseline was \>3, eGFR not more than 10% below Baseline GFR or within normal range and not a treatment failure and not a CRR. Non responder is reported when neither CRR nor PRR criteria was met. Percentage of participants reporting CRR, PRR and non responders at Week 104 has been presented.
Time frame: Week 104
Double-blind Period: Number of Participants Reporting On-treatment AEs and SAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with on-treatment AEs and SAEs has been reported.
Time frame: Up to Week 104
Double-blind Period: Number of Participants Reporting AESI
An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths. On-treatment data is displayed.
Time frame: Up to Week 104
This study evaluated safety and efficacy of intravenous (IV) belimumab 10 mg/kg plus standard of care (SoC) compared to placebo plus SoC in adult participants with active lupus nephritis. This was a Phase 3, multi-center, multi-national study consisting of a randomized, double-blind, placebo-controlled period and an open-label extension period. The study was conducted in 21 countries.
| Milestone | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 |
|---|---|---|
| Started | 224 | 224 |
| Completed | 170 | 186 |
| Not completed | 54 | 38 |
| Withdrew: Withdrawal by subject | 26 | 19 |
| Withdrew: Physician decision | 11 | 5 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Adverse event | 10 | 7 |
| Milestone | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 |
|---|---|---|
| Started | 123 | 132 |
| Completed | 122 | 124 |
| Not completed | 1 | 8 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Adverse event | 1 | 4 |
PERR is defined as urinary protein creatinine ratio \<=0.7, estimated glomerular filtration rate (eGRF) was not more than 20 percent (%) below the pre-flare value or \>=60 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2) and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates treatment group, induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline urine protein-creatinine ratio (uPCR), and Baseline eGFR. Modified Intent-to-treat (mITT) Population consisted of all randomized participants who received at least one dose of study treatment and were not excluded due to Good Clinical Practice (GCP) non-compliance. Percentage of participants with PERR at Week 104 has been presented.
| Percentage of participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Double-blind Period: Percentage of Participants With Primary Efficacy Renal Response (PERR) at Week 104 | 32.3 | 43.0 |
CRR is defined as urinary protein creatinine ratio \<0.5, eGRF was not more than 10% below the pre-flare value or \>=90 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), Baseline uPCR and Baseline eGFR. Percentage of participants with CRR at Week 104 has been presented.
| Percentage of participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Double-blind Period: Percentage of Participants With Complete Renal Response (CRR) at Week 104 | 19.7 | 30.0 |
PERR is defined as urinary protein creatinine ratio \<=0.7, eGRF was not more than 20% below the pre-flare value or \>=60 mL/min/1.73m\^2 and was not a treatment failure. Analysis was performed using a logistic regression model for the comparison between Belimumab and Placebo with covariates of induction regimen (CYC vs. MMF), race (Black vs. Non-Black), uPCR, and Baseline eGFR. Percentage of participants with PERR at Week 52 has been presented.
| Percentage of participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Double-blind Period: Percentage of Participants With PERR at Week 52 | 35.4 | 46.6 |
Events are defined as the first event experienced among the following: death, progression to end stage renal disease, doubling of serum creatinine from Baseline, renal worsening or renal-related treatment failure. Participants who discontinued randomized treatment, withdrew from the study, were lost to follow-up, or had a non renal-related treatment failure were censored. Participants who completed the 104-week treatment period were censored at the Week 104 visit. Time to event is defined as event date minus treatment start date plus one. Analysis was performed using Cox proportional hazards model for the comparison between Belimumab and Placebo adjusting for induction regimen, race, Baseline uPCR and Baseline eGFR. Number of participants with time to death or renal related event up to Week 104 has been presented.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Double-blind Period: Number of Participants With Time to Death or Renal Related Event | 63 | 35 |
ORR is defined with respect to reproducible responses that included CRR, partial RR (PRR) and non responder. CRR is reported when uPCR was \<0.5, eGFR was not more than 10% below pre-flare GFR or within normal range and not a treatment failure. PRR is \>=50% decrease from Baseline in uPCR and one of the following: value \<1 if Baseline \<=3, or value \<3 if the Baseline was \>3, eGFR not more than 10% below Baseline GFR or within normal range and not a treatment failure and not a CRR. Non responder is reported when neither CRR nor PRR criteria was met. Percentage of participants reporting CRR, PRR and non responders at Week 104 has been presented.
| Percentage of participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| CRR | 19.7 | 30.0 |
| PRR | 17.0 | 17.5 |
| Non responder | 63.2 | 52.5 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with on-treatment AEs and SAEs has been reported.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Any AE | 211 | 214 |
| Any SAE | 67 | 58 |
An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths. On-treatment data is displayed.
| Participants | Placebo | Belimumab 10 mg/kg |
|---|---|---|
| Malignancies excluding NMSC | 0 | 2 |
| Malignancies including NMSC | 0 | 3 |
| PISR | 29 | 26 |
| All infections of special interest | 34 | 30 |
| Depression/suicide/self-injury | 16 | 11 |
| Deaths | 3 | 4 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is any untoward medical occurrence that, at any dose: resulting in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Number of participants with AEs and SAEs have been reported.
| Participants | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|
| Any AE | 76 | 92 |
| Any SAE | 5 | 10 |
An AESI is one of scientific and medical concern specific to the product, for which ongoing monitoring and rapid communication by investigator to sponsor can be appropriate. A summary of protocol defined AESIs include malignant neoplasms including and excluding non-melanoma skin cancer (NMSC), post-infusion systemic reactions (PISR), all infections of special interest (opportunistic infections \[OI\], Herpes Zoster \[HZ\], tuberculosis \[TB\], and sepsis), depression (including mood disorders and anxiety)/suicide/self-injury and deaths.
| Participants | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|
| Malignancies excluding NMSC | 0 | 0 |
| Malignancies including NMSC | 0 | 0 |
| PISR | 4 | 5 |
| All infections of special interest | 2 | 6 |
| Depression/suicide/self-injury | 2 | 4 |
| Deaths | 1 | 0 |
Collected over All-cause mortality, non-SAEs and SAEs were summarised from the start of the first treatment up to Week 104 in double-blind period and from the first open-label dose up to Week 32 (8 weeks after last dose) in open-label extension period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 5/224 (2.2%) | 78/224 (34.8%) | 191/224 (85.3%) |
| Belimumab 10 mg/kg | 6/224 (2.7%) | 65/224 (29%) | 186/224 (83%) |
| Placebo to Belimumab 10 mg/kg | 1/123 (0.8%) | 5/123 (4.1%) | 34/123 (27.6%) |
| Belimumab 10 mg/kg to Belimumab 10 mg/kg | 0/132 (0%) | 10/132 (7.6%) | 39/132 (29.5%) |
| Event | Placebo | Belimumab 10 mg/kg | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 10/224 | 10/224 | 2/123 | 1/132 |
| Lupus nephritisRenal and urinary disorders | 8/224 | 2/224 | 0/123 | 0/132 |
| AnaemiaBlood and lymphatic system disorders | 6/224 | 1/224 | 0/123 | 0/132 |
| GastroenteritisInfections and infestations | 5/224 | 0/224 | 0/123 | 0/132 |
| Acute kidney injuryRenal and urinary disorders | 5/224 | 2/224 | 0/123 | 0/132 |
| Herpes zosterInfections and infestations | 2/224 | 4/224 | 0/123 | 1/132 |
| Lung infectionInfections and infestations | 4/224 | 2/224 | 0/123 | 0/132 |
| Urinary tract infectionInfections and infestations | 2/224 | 4/224 | 0/123 | 0/132 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 4/224 | 1/224 | 0/123 | 0/132 |
| CellulitisInfections and infestations | 3/224 | 0/224 | 0/123 | 1/132 |
| Event | Placebo | Belimumab 10 mg/kg | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 mg/kg |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 74/224 | 81/224 | 14/123 | 23/132 |
| DiarrhoeaGastrointestinal disorders | 48/224 | 45/224 | 0/123 | 0/132 |
| Urinary tract infectionInfections and infestations | 37/224 | 43/224 | 10/123 | 12/132 |
| NasopharyngitisInfections and infestations | 31/224 | 35/224 | 8/123 | 3/132 |
| HeadacheNervous system disorders | 35/224 | 34/224 | 0/123 | 0/132 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 32/224 | 26/224 | 5/123 | 7/132 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/224 | 30/224 | 0/123 | 0/132 |
| NauseaGastrointestinal disorders | 24/224 | 21/224 | 0/123 | 0/132 |
| HypokalaemiaMetabolism and nutrition disorders | 20/224 | 24/224 | 0/123 | 0/132 |
| GastroenteritisInfections and infestations | 23/224 | 21/224 | 0/123 | 0/132 |
| Age, Continuous(Years) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 | Total |
|---|---|---|---|
| Mean | 33.0 ± 10.64 | 33.7 ± 10.73 | 33.4 ± 10.68 |
| Sex: Female, Male(Participants) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 | Total |
|---|---|---|---|
| Female | 196 | 198 | 394 |
| Male | 28 | 26 | 54 |
| Race/Ethnicity, Customized(Participants) | Placebo to Belimumab 10 mg/kg | Belimumab 10 mg/kg to Belimumab 10 | Total |
|---|---|---|---|
| American Indian (AI) or Alaska Native (AN) | 6 | 4 | 10 |
| Asian-Central/South Asian Heritage (H) | 2 | 3 | 5 |
| Asian-Japanese/East Asian/Southeast Asian H | 107 | 112 | 219 |
| Mixed Asian | 1 | 0 | 1 |
| Black or African American (AA) | 31 | 30 | 61 |
| White/Caucasian/European H | 71 | 72 | 143 |
| White/Caucasian/Arabic/North African H | 4 | 1 | 5 |
| Multiple-AA/African H and AI or AN and White | 1 | 1 | 2 |
| Multiple-Asian and White | 1 | 1 | 2 |
Showing the first 100 of 118 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jul 2012 to primary completion in Jul 2019, 84 months.
Results were first posted in Jul 2020, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Human Genome Sciences Inc., a GSK Company →